O-221 Regenerative endometrial PRGF (plasma rich in growth factors) treatment in patients with thin endometrium, recurrent implantation failure, and recurrent miscarriages: a retrospective, self-controlled, cohort study

Abstract Study question What reproductive outcomes are observed in patients submitted to endometrial PRGF therapy due thin endometrium (ThE), recurrent implantation failure (RIF) and miscarriages (RM)? Summary answer Following treatment, success rates were significantly increased ThE RIF patients, whereas the RM group pregnancy loss not affected. is known already Adequate development of a functional prerequisite for successful embryo ART cycles. In contrast, management with lining or has been an ongoing challenge none proposed surgical, hormonal, pharmacological interventions achieving satisfactory results. recent years, use plasma rich growth factors (PRGF) - successfully applied other medical fields become novel treatment option medicine. It was used experimentally both ovarian follicle activation enhance receptivity although published studies small often contradictory design, size, duration All consecutive (n = 107) who underwent 150) single, private centre between 2016-2022 included this retrospective analysis. Patients recruited into 64), 36) 7) groups, respectively. Live birth / per transfer compared obtained previous transfers preceding intervention. External Ethics Committee approval comparative pilot study including above patient groups. Participants/materials, setting, methods by processing patients’ autologous blood sample in-house validated open system. Endometrial performed using thawed series intrauterine instillations (43%) combined approach performing hysteroscopic subendometrial infiltration during early follicular phase (57%). preparation conducted artificial hormone replacement protocol high-dose oral estrogens vaginal progesterone. Most involved vitrified-thawed blastocyst. Main results role chance A total 107 150 treatments 131 subsequent transfers. Altogether 19 (13%) cancelled, higher than (16 vs 7.1%). (64 98 cycles controls), positive (41 32%, NS), clinical (35 22%, p 0.049) pregnancy/live (24 4.7%, < 0.0001) (36 42 101 (59 20%, 0.0001), (44 11%, (33 7.9%, (7 10 15 (50 60%), (20 27%) (0 0%) different no pregnancies achieved. So far, 20 singletons 1 set twins have confirmed be born from (12 still ongoing). Limitations, reasons caution Heterogeneity severity could affect outcomes. The self-controlled design might influenced comparison pre-, post-intervention rates, also highlights poor-prognostic nature participants. too few evaluate rates. Wider implications findings This preliminary, shown that regenerative safe, affordable, efficient patients. Further randomized warranted, they hampered selection issues lack applicable options non-intervention group. Trial registration number